Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

A list of downloadable documents created during development.

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...

Bearish flow noted in GSK (GSK) Pharma with 6,103 puts trading, or 5x expected. Most active are 3/14 weekly 39.5 puts and Mar-25 41.5 calls, with total volume in those strikes near 5,500 contracts.

The 5-second intravenous bolus offers faster, simpler administration than Activase. (HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...